Why the study?
Does glimepiride improve glycemic control in patients with NIDDM previously treated with sulfonylureas?
Does glimepiride improve glycemic control in patients with NIDDM previously treated with sulfonylureas?
Glimepiride at doses of 1, 4, and 8 mg once daily provides significant, dose-dependent improvements in glycemic control in patients with NIDDM.
Answers are grounded in this paper and cite their sources.
Supports glimepiride for glycemic control in sulfonylurea-pretreated NIDDM; confirms dose-dependent efficacy in this RCT population.
OBJECTIVE: To assess the efficacy, safety, and dose-response relationship of glimepiride in patients with NIDDM. RESEARCH DESIGN AND METHODS: After a 21-day placebo washout period, 304 patients were randomized to receive either placebo or glimepiride, 1, 4, or 8 mg once daily. Fasting plasma glucose (FPG), 2-h postprandial glucose (PPG), and HbA1c were measured at predetermined intervals during the washout period and the 14-week study. Adverse events were tabulated. RESULTS: At each patient visit, reduction from baseline FPG was greater in each glimepiride group than in the placebo group (P < 0.001). Changes from baseline to endpoint after 1, 4, and 8 mg glimepiride exceeded those after placebo (P < 0.001) by 2.4, 3.9, and 4.1 mmol/l, respectively, for FPG; by 1.2, 1.8, and 1.9 percentage points, respectively, for HbA1c; and by 3.5, 5.1, and 5.2 mmol/l, respectively, for 2-h PPG. Greater reductions in these parameters were observed with 8 and 4 mg than with 1 mg (P < 0.05), indicating a dose-response relationship. When patients with baseline HbA1c levels > or = 8% were assessed, more patients who received 8 mg glimepiride had HbA1c values < 8% at endpoint compared with patients receiving 4 mg. Glimepiride had a favorable safety profile. CONCLUSIONS: Glimepiride in 1-, 4-, or 8-mg doses was effective and well tolerated. Although the 4- and 8-mg once-daily doses were significantly more potent than the 1-mg dose, all three doses yielded clinical improvement. Because the 8-mg dose controlled HbA1c values in a greater number of patients with high baseline HbA1c levels than did the 4-mg dose, this higher dose might be beneficial for patients who are difficult to treat.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: